Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-21 07:54 am Unchanged |
2025-04-21 | 13D | Immunovant, Inc. IMVT |
Roivant Sciences Ltd. ROIV |
96,660,341 56.900% |
0 (Unchanged) |
Filing History |
| 2025-02-25 07:19 am Unchanged |
2025-02-21 | 13D | Arbutus Biopharma Corporation ABUS |
Roivant Sciences Ltd. ROIV |
38,847,462 20.500% |
0 (Unchanged) |
Filing History |
| 2025-02-18 5:21 pm Unchanged |
2025-02-18 | 13D | Arbutus Biopharma Corporation ABUS |
Roivant Sciences Ltd. ROIV |
38,847,462 20.500% |
0 (Unchanged) |
Filing History |
| 2025-02-14 2:00 pm Sale |
2024-12-31 | 13G | Roivant Sciences Ltd. ROIV |
QVT Financial LP | 65,793,779 9.220% |
-926,000 (-1.39%) |
Filing History |
| 2025-02-14 09:59 am Sale |
2024-12-31 | 13G | Roivant Sciences Ltd. ROIV |
SB INVESTMENT ADVISERS (UK) LTD | 62,057,537 8.500% |
-10,974,130 (-15.03%) |
Filing History |
| 2025-01-15 4:30 pm Purchase |
2025-01-13 | 13D | Immunovant, Inc. IMVT |
Roivant Sciences Ltd. ROIV |
96,660,341 56.900% |
16,845,010 (+21.10%) |
Filing History |
| 2024-11-14 4:31 pm Sale |
2024-09-30 | 13G | Roivant Sciences Ltd. ROIV |
VIKING GLOBAL INVESTORS LP | 54,099,066 7.300% |
-15,269,895 (-22.01%) |
Filing History |
| 2024-11-12 4:58 pm Unchanged |
2024-09-30 | 13G | Roivant Sciences Ltd. ROIV |
The Vanguard Group | 41,683,055 5.630% |
0 (Unchanged) |
Filing History |
| 2024-11-12 10:34 am Purchase |
2024-11-08 | 13G | Roivant Sciences Ltd. ROIV |
FMR LLC | 49,145,056 6.645% |
49,145,056 (New Position) |
Filing History |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | Roivant Sciences Ltd. ROIV |
BlackRock Inc. BLK |
41,962,059 5.700% |
0 (Unchanged) |
Filing |
| 2024-11-04 10:47 am Purchase |
2024-09-30 | 13G | Roivant Sciences Ltd. ROIV |
The Vanguard Group | 41,683,055 5.630% |
41,683,055 (New Position) |
Filing History |
| 2024-10-24 2:02 pm Purchase |
2024-09-30 | 13G | Roivant Sciences Ltd. ROIV |
BlackRock Inc. BLK |
41,962,059 5.700% |
41,962,059 (New Position) |
Filing |
| 2024-04-02 4:06 pm Sale |
2024-04-02 | 13G | Roivant Sciences Ltd. ROIV |
Sumitomo Chemical Co. Ltd. | 0 0.000% |
-71,251,083 (Position Closed) |
Filing History |
| 2024-03-07 5:33 pm Sale |
2024-03-07 | 13G | Roivant Sciences Ltd. ROIV |
QVT Financial LP | 66,719,779 8.280% |
-45,821,757 (-40.72%) |
Filing History |
| 2024-02-14 4:46 pm Unchanged |
2023-12-31 | 13G | Roivant Sciences Ltd. ROIV |
Ramaswamy Vivek | 81,454,521 9.750% |
0 (Unchanged) |
Filing History |
| 2024-02-14 11:14 am Sale |
2023-12-31 | 13G | Roivant Sciences Ltd. ROIV |
QVT Financial LP | 112,541,536 13.970% |
-10,000,000 (-8.16%) |
Filing History |
| 2024-02-14 10:20 am Sale |
2023-12-31 | 13G | Roivant Sciences Ltd. ROIV |
VIKING GLOBAL INVESTORS LP | 69,368,961 8.600% |
-5,869,739 (-7.80%) |
Filing History |
| 2024-02-14 06:51 am Unchanged |
2023-12-31 | 13G | Roivant Sciences Ltd. ROIV |
Dexcel Pharma Technologies Ltd. | 102,849,443 12.780% |
0 (Unchanged) |
Filing History |
| 2024-02-13 5:26 pm Sale |
2023-12-31 | 13G | Roivant Sciences Ltd. ROIV |
Ramaswamy Vivek | 81,454,521 9.750% |
-328,720 (-0.40%) |
Filing History |
| 2024-02-13 5:00 pm Sale |
2023-12-31 | 13G | Roivant Sciences Ltd. ROIV |
SB INVESTMENT ADVISERS (UK) LTD | 73,031,667 9.100% |
-22,000,000 (-23.15%) |
Filing History |